N/A N=19 Visualizing Vascular Mechanisms of Salt Sensitivity
Obesity · Cardiovascular Risk Factor · Salt; Excess
Primary: Mean Arterial Blood Pressure Following High-salt Diet and Low-salt Diet — 83.3; 89.5 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=59 Tissue Sodium in Pre-hypertensive Patients
Hypertension
Primary: Change in Tissue Sodium Concentration Measured Using Sodium Magnetic Resonance Imaging (NaMRI) — -0.202; 0.430; -1.745; -0.407 mmol/L
N/A N=12 Central Sodium Sensing: Implications for Blood Pressure Regulation
Salt Sensitivity of Blood Pressure
Primary: Functional Connectivity Between the Subfornical Organ and Organum Vasculosum of the Lamina Terminalis (Z-score) — 0.258490; 0.359145; 0.207372; 0.169055 z-score
Phase 4 N=132 Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
Hypertension
Primary: Mean 24 Hour Ambulatory Systolic Blood Pressure (MASBP) in Systolic Hypertensive Patients Treated With Aliskiren (300 mg) for 4 Weeks on a High Sodium Diet Versus 4…
N/A N=38 Dietary Salt in Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: Plasma Volume — 2805; 3032; 2362; 2633 mL
N/A N=17 Efficacy of Dietary Sodium Restriction of Improving Vascular Endothelial Function in Middle Aged and Older Adults
Hypertension
Primary: Improved Flow Mediated Dilation — 3.57; 6.01 percentage dilation
Phase 4 N=12 The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure
Hypertension
Primary: Mean Arterial Pressure — 88; 87; 87; 87 mm Hg
Phase 4 N=90 Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN
Hypertension · Genetics Hypertension
Primary: Systolic /Diastolic Supine Morning Liberal Salt Automated Blood Pressure — 144.2; 148.5; 86.0; 91.4 mm hg — p=0.823
N/A N=20 The Effect of Sodium Reduction on Blood Pressure and Physical Function in Older Adults
Hypertension · Physical Disability · Aging
Primary: Seated Blood Pressure — 112.1; 116.1; 60.3; 60.4 mmHg
Phase 3 N=992 SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)
Hypertension
Primary: Number of Patients Achieving Target Blood Pressure at Week 14 From Baseline — 276; 270; 116; 87 Participants — p=0.118
N/A N=36 Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African Americans Study (GENE-FORECAST): Sodium Intervention Trial (SIT)
Cardiovascular Disease
Primary: Mean Change in Vascular Function Measured by Pulse Wave Velocity — 7.08; 7.13; 7.34; 7.07 m/s — p=0.98
N/A N=323 Stress, Salt Excretion, and Nighttime Blood Pressure
Blood Pressure · Psychological Stress
Primary: Ratio of Awake-to-asleep Urinary Sodium Excretion Rate (Aim 1) — 1.4 Ratio of awake-to-asleep — p=0.0032
Phase 2 N=14 The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension
Hypertension
Primary: Muscle Sympathetic Nerve Activity at Rest — 41; 43.8 bursts/minute
Phase 4 N=256 Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan
Hypertension · Chronic Kidney Disease · Microalbuminuria
Primary: ∆Albuminuria by 24-hour Urine Protein Excretion — 483.5; 569.9; 487.3; 417.4 mg/day — p=0.006
Phase 4 N=24 Nebivolol Versus Metoprolol: Sodium Sensitivity
Hypertension
Primary: Change in 24-hour Mean Systolic Blood Pressure by ABPM From Day 5 of Low Sodium to Day 10 of High Sodium — 7.7; 9.3 mmHg
N/A N=27 Effect of Dietary Sodium Intake on Vascular Endothelium
Postural Tachycardia Syndrome (POTS)
Primary: FMD (% Change) — 12.75; 11.65; 11.43; 12.75 percentage of change
N/A N=14 Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure
Diastolic Heart Failure · Hypertensive Heart Disease
Primary: Brachial Artery Flow-mediated Dilation (FMD) — 5; 8 % dilation — p=.17
N/A N=126 Blood Pressure in Dialysis Patients
Hypertension · Renal Failure Chronic Requiring Hemodialysis · Blood Pressure
Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants
N/A N=18 Dietary Salt in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change in Tissue Sodium — 17.1; 16.7 mmol/L — p=0.55
N/A N=38 Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: 24hr Urinary Sodium — 16.8; 280; 14.7; 245 milliequivalents
Phase 4 N=41 DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
Diabetes Mellitus · Diabetic Kidney Disease · Hypertension
Primary: To Investigate the Modifying Effect of Sodium Intake on Ertugliflozin on Blood Pressure — 125; 121; 138; 133 mmHg — p=0.0174
Phase 2 N=72 Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension
Salt-sensitive Hypertension
Primary: Cumulative Sodium Excretion (Natriuresis) at Day 1 — 61.26; 37.13; 188.87; 138.92 mmol
N/A N=179 Intervention to Reduce Dietary Sodium in Hemodialysis
Renal Dialysis
Primary: Time Specific Interdialytic Weight Gain (Baseline) — 1.2; 1.2 kg/day
N/A N=19 Conventional Hemodialysis vs. Short Daily Hemodialysis (6 Days / Week) and Mechanisms of Blood Pressure Control
End Stage Renal Disease
Primary: Mean Systolic Blood Pressure Over the Third Month of Each Treatment Arm — 139; 142 mm Hg
Phase 2 N=50 Blood Pressure Lowering in Dialysis (BOLD) Trial
Blood Pressure · End Stage Renal Disease on Dialysis (Diagnosis) · Chronic Kidney Diseases
Primary: Feasibility - Screen:Enrollment Ratio — 50 Participants
N/A N=139 Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients
Intra-dialytic Hypotension
Primary: Change in Intra-dialytic Decline in Systolic Blood Pressure — 26; 23 mm Hg
N/A N=17 Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Obstructive Sleep Apnea · Resistant Hypertension · Hyperaldosteronism
Primary: Severity of Obstructive Sleep Apnea — -18.3; 7.0 events/hour
Phase 2 N=160 Chlorthalidone in Chronic Kidney Disease
Renal Insufficiency, Chronic · Hypertension
Primary: Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo. — -11.0; -0.5 mm Hg
Phase 4 N=30 Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension
PreDiabetes · Prehypertension
Primary: 24-hours Systolic Blood Pressure at Week 12 — 117; 120 mmHg — p=0.755
Phase 4 N=30 Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension
Hypertension
Primary: 24-hour Average Systolic Blood Pressure — 127; 127; 126; 129 mmHg